Funding Announcements

"Current treatments for these conditions require frequent hospitalisations for intravenous treatment with high doses of diuretics which is not only inconvenient for patients and associated with a risk of kidney injury but also costly. We offer a gentler, safer solution that can be delivered at home, offering patients better quality of life and reducing hospital admissions and costs to healthcare providers. This round of funding enables Renephra to carry out pilot clinical studies to demonstrate a viable success rate in target patients and to understand factors related to success. This is an essential next step for the company in advancing this much needed and promising technology through to regulatory approvals and making it available to clinicians and patients."

"As a clinical services-led company, C7 Health’s mantra is to work shoulder-to-shoulder with healthcare providers to deliver solutions that will benefit patients – rather than develop products that are great in theory, but fail to make a real difference."

"Healx has a simple but profound goal: To transform the lives of rare disease patients. Our technology helps us find treatments where none currently exist,"

"Right now, too many people are waiting weeks or even months for care – this causes incredible stress for people and their families, and it’s also a huge expense to our health system. People deserve better than this broken status quo and we know that our technology can help."